Edward Kiggundu, MD
Radiation Oncology · Martinsburg, WVNPI 1316933492
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by AstraZeneca at 44.0% of the total. 2023 is the largest year on record at $87, 6.5 times the $13 reported in 2020. That places this record below the midpoint for radiation oncology clinicians in WV, where the typical reported total is $295.
Across 5 payments — averaging $32.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$71
- Progenics Pharmaceuticals, Inc.$51
- Novocure Inc.$40
What the payments were for
- Food & beverage$162100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $71 |
| Progenics Pharmaceuticals, Inc. | 1 | $51 |
| Novocure Inc. | 3 | $40 |
How this compares
$162 in reported general payments places this provider in the 25th percentile of 29 radiation oncology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lidocaine Hcl ViscousLidocaine Hcl | 17 | $499 |
| Silver Sulfadiazine | 19 | $291 |
| Tamsulosin Hcl | 19 | $157 |
| SsdSilver Sulfadiazine | 12 | $135 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Martinsburg
- John VarlottoHuntington$120K
- Gregory MerrickWheeling$21K
- David ShimmBeckley$5K
- Paul AdedoyinHuntington$3K
- Benjamin YanMorgantown$2K
- Michael GallowayElkins$1K
- Jondavid PollockWheeling$1K
- Jon-Michael StorkMorgantown$1K
- Sanjeev SharmaHuntington$1K
- Greeshma Rajeev-KumarWheeling$891
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.